Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-09-24 | NCT07482176 | |
| Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, macular degeneration, nervous system disorder, retinal degeneration, retinal disorder, vision disorder | Recruiting | Phase 2 | 2026-08-05 | NCT07630649 | |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06856577 | |
| Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), choroidal neovascularization, eye disorder, macular degeneration, nervous system disorder, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, vision disorder, wet macular degeneration | Active, not recruiting | Not stated | 2026-02-10 | NCT04645212 | |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] | Metaplasia, Neovascularization, Pathologic, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), choroidal neovascularization, eye disorder, macular degeneration, nervous system disorder, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 2 | 2025-08-22 | NCT05536973 | |
| Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) | Diabetes Complications, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), cardiovascular disorder, diabetes mellitus, diabetic macular edema, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, nervous system disorder, retinal disorder, vascular disorder, vision disorder | Active, not recruiting | Not stated | 2025-04-22 | NCT05607810 |